Samuel Urrutia

Assistant Professor of Medicine

Washington University in St. Louis
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (19)

Year:

2026

Year:

2025

TP53 mutations are found in 10% to 15% of myeloid neoplasms and are one of its most important prognostic factors. Emerging data show that TP53 mutational allele status is a key determinant of clinical outcomes, with multihit TP53 mutant myeloid neoplasms having a very poor prognosis. Significant differences exist among the methods used in clinical and research settings to assess TP53 mutational status, leading to variability in reported patient characteristics, response to therapy, and survival. Indeed, differences in the criteria used to define TP53 mutational states among professional societies and in landmark research studies have led to confusion, suboptimal clinical testing, and variability in therapy recommendations. We review the methods used to assess for TP53 mutational allele status and provide recommendations, based on clinically available testing, for the accurate evaluation of TP53 gene mutations in myeloid neoplasms. Hotspot mutations represent ∼35% of all TP53 missense mutations in myeloid neoplasms. There is evidence that these hotspot mutations may have dominant-negative or gain-of-function properties. Here, we review this evidence and discuss the potential impact of TP53 mutation identity on patient outcomes and clinical management.

Year:

2025

Background: Acute promyelocytic leukemia (APL) is prevalent in Latin America and carries a high risk of early-onset complications. However, outcome data for APL in this region are limited. Since 2020, Chile has adopted all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) as the standard therapy for APL. In this real-world study, we describe the characteristics, survival outcomes, and causes of death (COD) for adult APL patients in Chile. Methods: This multicenter, retrospective study analyzed data from 174 adult patients diagnosed with APL across 16 public institutions in Chile between 2013 and 2024. Causes of death were obtained from electronic medical record reviews and death certificates. Time-to-event analyses were conducted using the log-rank test and Kaplan-Meier survival estimates. Results: Of the 174 patients, 90 (52%) were male. The median age at diagnosis was 41 years (IQR: 32–56). Patient distribution by region was as follows: Metropolitan (56%), Biobío (14%), Valparaíso (8.6%), and Antofagasta (6.9%). The incidence of APL was higher in the northern region of Antofagasta at 2 cases per 100,000 inhabitants, compared to a range of 0.9–1.2 per 100,000 in other regions. The t(15;17) translocation was confirmed in 149 patients (86%). Trisomy 8 was found in 21 patients (12%), and a complex karyotype was present in 16 patients (9.2%). The median overall survival (mOS) for the cohort was 2.55 years (IQR: 0.8–5.6). In the multivariate analysis, sex, year of diagnosis, and other cytogenetic abnormalities were not statistically significant predictors of survival (p>0.05). At the time of analysis, 39 patients (22%) were deceased. Of these deaths, 29 (74%) occurred within the first 30 days (early mortality). The proportion of early deaths was 78% (22 of 28 total deaths) prior to the adoption of the ATRA/ATO regimen, compared to 63% (7 of 11 total deaths) after its adoption. The most common COD were bleeding (n=14, 48%), respiratory failure (n=4, 14%), and sepsis (n=2, 6.9%). Conclusion: In this cohort, mortality was primarily driven by early complications, particularly bleeding and respiratory failure. The higher incidence of APL in the Antofagasta region warrants further investigation. Although the adoption of ATRA/ATO lowered overall mortality, early deaths from bleeding remains high. Early recognition of and intervention for coagulopathy are critical to improving survival outcomes in this population

Year:

2025

Year:

2025

Purpose: Hypomethylating agents (HMA) combined with venetoclax are an emerging therapeutic strategy for higher-risk myelodysplastic syndromes (HR-MDS). The cytogenetic and molecular factors associated with outcomes with this combination for HR-MDS are incompletely understood. Experimental Design: We pooled patient data from 3 prospective trials evaluating HMA–venetoclax in HR-MDS to study associations between cytogenetic and molecular factors and overall response rate (ORR), overall survival (OS), and event-free survival (EFS). The Kaplan–Meier method was used to estimate time-to-event endpoints. Univariate and multivariate analyses using logistic regression (for ORR) or the Cox proportional hazards model (for OS and EFS) were used to identify associations between clinical, cytogenetic, and molecular factors and outcomes. Results: A total of 80 patients (52 HMA-naïve, 28 HMA-failure) were included. ORR was 90% in HMA-naïve and 57% in HMA-failure. Median OS was 28.2 and 8.3 months in HMA-naïve and HMA-failure, respectively. Median EFS was 17.9 and 5.5 months in HMA-naïve and HMA-failure, respectively. In addition, 24/52 (46%) of the HMA-naïve and 3/28 (11%) of the HMA-failure patients proceeded to allogeneic stem cell transplantation (SCT). Factors associated with inferior outcomes were prior HMA failure, complex cytogenetics, trisomy 8, TP53 mutations, and RAS pathway mutations. Mutations in RNA splicing, DNA methylation, and ASXL1 appeared favorable. Blast percentage was not predictive of outcomes. Conclusions: Knowledge of cytogenetic and molecular alterations may help identify which patients with HR-MDS benefit the most from venetoclax.

Year:

2024

Therapy-related myeloid neoplasms (t-MNs) arise after exposure to cytotoxic therapies and are associated with high-risk genetic features and poor outcomes. We analyzed a cohort of patients with therapy-related chronic myelomonocytic leukemia (tCMML; n = 71) and compared its features to that of de novo CMML (dnCMML; n = 461). Median time from cytotoxic therapy to tCMML diagnosis was 6.5 years. Compared with dnCMML, chromosome 7 abnormalities (4% vs. 13%; P = .005), but not complex karyotype (3% vs. 7%; P = .15), were more frequent in tCMML. tCMML was characterized by higher TP53 mutation frequency (4% vs. 12%; P = .04) and lower NRAS (6% vs 22%, P =0.007) and CBL (4% vs 12%, P =0.04) mutation frequency. Prior therapy with antimetabolites (OR, 1.22 [95% CI, 1.05-1.42]; P = .01) and mitotic inhibitors (OR, 1.24 [95% CI, 1.06-1.44]; P = .009) was associated with NF1 and SETBP1 mutations while prior mitotic inhibitor therapy was associated with lower TET2 mutation frequency (OR, 0.71 [95% CI, 0.55-0.92]; P = .01). Although no differences in median overall survival (OS) were observed among tCMML and dnCMML (34.7 months vs 35.9 months, P = .26), multivariate analysis for OS revealed that prior chemotherapy was associated with increased risk of death (HR 1.76 [95% CI, 1.07-2.89]; P = .026). Compared to a cohort of therapy-related myelodysplastic syndrome, tCMML had lower TP53 mutation frequency (12% vs 44.4%, P <.001) and less unfavorable outcomes. In summary, tCMML does not exhibit the high-risk features and poor outcomes of t-MNs. -

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (24)

Gautam Borthakur

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Hagop Kantarjian

-

UNITED STATES
View details

Hussein A. Abbas

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Georgina Gener-Ricos

Assitant Professor

Institut Català d'Oncologia

SPAIN
View details

Alex Bataller Torralba

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ghayas C. Issa

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Guillermo Montalban-Bravo

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Rashmi Kanagal Shamanna

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sanam Loghavi

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Daniel C. Link

Washington University School of Medicine

UNITED STATES
View details

Koji Sasaki

Chair and Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Farhad Ravandi

Professor of Medicine, Chief Section of AML

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elizabeth Griffiths

Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Ziyi Li

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Amer M. Zeidan

Yale University School of Medicine

UNITED STATES
View details

Nicholas J. Short

-

UNITED STATES
View details

Wei-Ying Jen

National Cancer Institute

SINGAPORE
View details

Yesid Alvarado Valero

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Tapan M. Kadia

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elias J. Jabbour

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Courtney D. DiNardo

University of Pennsylvania

UNITED STATES
View details

Guillermo Garcia-Manero

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sangeetha Venugopal

Assistant professor

Sylvester Comprehensive Cancer Center

UNITED STATES
View details

Naval G. Daver

Professor of Medicine

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details